Over the past decade, there has been an explosion in transgender medical infrastructure across the United States and world to “treat” transgender people. In addition to gender clinics proliferating across the United States, hospital wings are being built for specialized surgeries, and many medical institutions are clamoring to get on board with the new developments. Doctors are being trained in cadaver symposiums across the world in all manner of surgeries related to transgender individuals, including phalloplasty, vaginoplasty, facial feminization surgery, urethral procedures, and more. More and more American corporations are covering transgender surgeries, drugs, and other expenses. Endocrinologists seeking the fountain of youth in hormones for more than a generation, and the subsequent earnings for marketing those hormones, are still on a quest for gold.
Puberty blockers are another growing market. The plastic surgery arm of medicine is staged for an infusion of cash as well as organ transplants, especially womb transplants for men identifying as women who may want future pregnancies. These surgeries are already being practiced on animals and the first successful womb implant from a deceased female donor to another female has already been a success. Biogenetics is poised to be the investment of the future, says Rothblatt, who has headed a massive pharmaceutical corporation and is now heavily invested in biogenetics and transplants.
Transgenderism has certainly made its way into the American marketplace, so it seems important to consider the implications of this as we pass laws regarding transgender individuals’ and our civil liberties. Transgenderism sits square in the middle of the medical industrial complex, which is by some estimates even bigger than the military industrial complex.
Much more important than funds going directly to the LGBT lobby and organizations, only a fraction of which trickles down to assist people who identify as transgender, is the money invested by the men mentioned above, governments, and technology and pharmaceutical corporations to institutionalize and normalize transgenderism as a lifestyle choice. They are shaping the narrative about transgenderism and normalizing it within the culture using their funding methods.